ArticleDiagnostic pathology2014
Decreased microRNA-224 and its clinical significance in non-small cell lung cancer patients.
Article in Diagnostic pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- MiR-224 promotes lymphatic metastasis by targeting ANGPTL1 in non-small-cell lung carcinoma.Cancer biomarkers : section A of Disease markers · 2022Article
- Circ_0017639 facilitates proliferative, migratory, and invasive potential of non-small cell lung cancer (NSCLC) cells via PI3K/AKT signaling pathway.Bioengineered · 2022Article
- Retraction Note: Decreased miR-154 expression and its clinical significance in human colorectal cancer.World journal of surgical oncology · 2019Article
- Retraction Note: Decreased microRNA-452 expression and its prognostic significance in human osteosarcoma.World journal of surgical oncology · 2019Article
- Expression of Concern to: Increased expression of LncRNA BANCR and its prognostic significance in human hepatocellular carcinoma.World journal of surgical oncology · 2019Article
- Expression of Concern to: Decreased microRNA-224 and its clinical significance in non-small cell lung cancer patients.Diagnostic pathology · 2019Article
- MicroRNA in Lung Cancer Metastasis.Cancers · 2019Review
- Serum starvation induces cell death in NSCLC via miR-224.OncoTargets and therapy · 2019Article
- miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC.Nature communications · 2018Article
- Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy.Oncology letters · 2018Article
- MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9.Oncotarget · 2017Article
- MicroRNA-338-3p suppresses cell proliferation and induces apoptosis of non-small-cell lung cancer by targeting sphingosine kinase 2.Cancer cell international · 2017Article
- Epigenetics in non-small cell lung cancer: from basics to therapeutics.Translational lung cancer research · 2016Review
- MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4.American journal of cancer research · 2016Review
- MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7.Oncotarget · 2015Article
- MicroRNA-224: as a potential target for miR-based therapy of cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- MicroRNA-153 expression and prognosis in non-small cell lung cancer.International journal of clinical and experimental pathology · 2015Article
- Bioinformatics-based identification of potential microRNA biomarkers in frequent and non-frequent exacerbators of COPD.International journal of chronic obstructive pulmonary diseaseArticle
Corrections and comments
- Expression of concern · 2019-05-30Author Unresponsive · Duplication of/in Image ·
- Expression of concern
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNA-224 has been proven dysregulated in some human malignancies and correlated with tumor progression. However, its expression and clinical significance in non-small cell lung cancer (NSCLC) is still unclear. Thus, the aim of this study was to explore the effects of miR-224 in NSCLC tumorigenesis and development.
methodsUsing real-time quantitative RT-PCR, we detected miR-224 expression in NSCLC cell lines and primary tumor tissues. The association of miR-224 expression with clinicopathological factors and prognosis was also statistically analyzed. MTT, flow cytometric, Transwell invasion and migration assays, and scratch migration assay were used to test the proliferation, apoptosis, invasion, and migration of NSCLC cells after miR-224 mimics transfection.
resultsMiR-224 expression levels were significantly down-regulated in NSCLC compared to the corresponding noncancerous lung tissues (P <0.001). In addition, decreased miR-224 expression was significantly associated with lymph node metastasis (P = 0.002), advanced TNM stage (P <0.001), and shorter overall survival (P <0.001). Multivariate regression analysis corroborated that down-regulation of miR-224 was an independent unfavourable prognostic factor for patients with NSCLC. Furthermore, transfection of miR-224 mimics in NSCLC A549 cells was able to reduce cell proliferation, invasion, and migration, and promote cell apoptosis.
conclusionsThese findings indicate that miR-224 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for miR-based therapy of NSCLC. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_198.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.